For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230523:nRSW2677Aa&default-theme=true
RNS Number : 2677A Benchmark Holdings PLC 23 May 2023
Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014 and
Article 7 of the UK version of EU Regulation 596/2014 which forms part
of UK law by virtue of the European Union (Withdrawal) Act 2018.
23 May 2023
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Second Quarter and Interim results for the six months ended 31 March 2023
Strong Q2 and H1 results continuing track record of quarterly growth and
strategic delivery
Benchmark (LSE: BMK), the aquaculture biotechnology company, announces its
unaudited interim results for the six months ended 31 March 2023 (the "Period"
or "H1 FY23"). The Company also announces its unaudited results for the three
months ended 31 March 2023 ("Q2 FY23") in compliance with the terms of its
unsecured Green bond.
Financial highlights
· Excellent H1 FY23 results driven by good performance in all business
areas:
o 25% growth in revenues to £98.9m (H1 FY22: £79.2m)
o 39% increase in Adj. EBITDA to £22.1m (H1 FY22: £15.9m)
o 47% increase in Adj. EBITDA excluding fair value ("FV") movement in
biological assets to £21.8m (H1 FY22: £14.8m):
§ Adj. EBITDA margin excluding FV movement in biological assets increased to
22% (H1 FY22: 19%)
o 193% increase in Adj. Operating profit excluding FV movement in biological
assets to £11.4m (H1 FY22: £3.9m)
o Further reduction in loss before tax
o Operating cash inflow £9.5m (H1 FY22: cash inflow of £2.0m)
· Strong Q2 FY23 performance building on track record of continuous
quarterly improvement:
o Revenues +13% to £44.4m (Q2 FY22: £39.2m)
o Adj. EBITDA +32% to £11.1m (Q2 FY22: £8.4m); Adj. EBITDA margin of 25%
in line with medium term target set in May 2022
o Adj. EBITDA excluding FV movement in biological assets +32% to £9.7m (Q2
FY22: £7.3m); Adj. EBITDA margin excluding FV movement in biological assets
of 22% (Q2 2022: 19%)
o Adj. Operating profit excluding fair value movement in biological assets
+244% to £4.5m (Q2 FY22: £1.3m)
· Net debt (excluding lease liabilities) continues to reduce to £44.5m
(30 September 2022: £47.5m; 31 March 2022: £50.6m):
o Cash of £41.9m and liquidity (cash and available facility) of £53.9m at
22 May 2023
Business Area highlights
· Genetics - strong performance in core salmon business and strategic
progress in growth areas:
o H1 FY23 Revenues +30% driven by higher salmon sales from Norway and
Iceland; 181m salmon eggs sold (H1 FY22: 134m)
o Continued commercial progress in Chile with new customer wins
o Obtained "disease free compartment status" from the Chilean regulator, an
important biosecurity endorsement which will enable the Company to export
salmon eggs from Chile
o Completed configuration at Salten, Norway facility to reach 150m salmon
eggs production capacity from FY24 (currently 140m), ahead of plan
o Total salmon egg capacity now 400m eggs, comprising 150m in Norway, 200m
in Iceland and 50m in Chile
o Strengthened scientific team to progress positioning on new technologies;
enhanced genotyping capabilities
· Advanced Nutrition - strong performance despite soft shrimp markets
demonstrates success of commercial focus and agile operation:
o Marginally lower revenues in Q2 FY23 albeit 8% higher revenues for H1 FY23
as a whole
o Strong performance in marine fish species which represent c.25% of
revenues
o Uplift in shrimp market expected as inventory levels normalise along the
global supply chain and consumer confidence improves
· Health - strong result from combined sea lice product portfolio and
integrated commercial team:
o Continuing adoption of Ectosan® Vet and CleanTreat® supported by
excellent efficacy resulting in H1 FY23 sales of £12.9m, up 50% on last year
o Progress on development of streamlined integrated CleanTreat®
infrastructure with partners MMC and Salt Ship Design
o Strong sales of Salmosan® Vet driven by success of new marketing label
Current trading and outlook
· On track to deliver strong growth for the year in line with market
expectations:
o Good visibility of salmon egg sales from Norway and Iceland
o Market conditions in shrimp are expected to remain unchanged in the short
term; well positioned for resilience and market share wins. Positive backdrop
in the Mediterranean marine fish market
o Expect Q3 FY23 sales from Ectosan® Vet and CleanTreat® to reflect low
sea lice treatment season, thereafter increasing in Q4 FY23
· Update on Oslo Børs uplisting:
o Consultation with shareholders regarding a potential delisting from AIM
and uplisting to Oslo Børs completed
o Plan to maintain a dual listing on Euronext Growth Oslo and on AIM for the
foreseeable future. Uplisting to Oslo Børs will be reviewed as part of
ongoing strategy to enhance Group positioning and share performance
£m % CER Q2 FY22 % CER
H1 FY23 H1 FY22 H1 FY23 Q2 FY23 Q2 FY23
Revenue 98.9 79.2 +19% 44.4 39.2 +9%
+25% +13%
Adjusted
Adjusted EBITDA(1) 22.1 15.9 +36% 11.1 8.4 +28%
+39% +32%
Adj. EBITDA excluding biological asset fair value movements 21.8 14.8 +42% 9.7 7.3 +28%
+47% +32%
Adjusted Operating profit(2) 11.7 4.9 +130% 5.9 2.4 +134%
+138% +145%
Adj. Operating profit excluding biological asset fair value movements 11.4 3.9 180% 4.5 1.3 220%
+193% +244%
Statutory
Operating profit/(loss) 0.3 (2.2) +97% 0.4 (0.7) +122%
+114% +159%
Loss before tax (1.9) (5.1) +65% (2.0) (1.5) -56%
+63% -38%
Basic loss per share (p) (0.57) (1.32) (0.40) (0.54)
Net debt(3) (66.3) (81.4) (66.3) (81.4)
Net debt(3) excluding lease liabilities (44.5) (50.6) (44.5) (50.6)
Business Area summary
£m %CER* % CER*
H1 FY23 H1 FY22 H1 FY23 Q2 FY23 Q2 FY22 Q2 FY23
Revenue
Advanced Nutrition 45.3 42.0 -4% 22.6 23.0 -10%
+8% -1%
Genetics 34.5 26.6 +31% 13.0 11.4 +16%
+30% +14%
Health 19.1 10.7 +79% 8.7 4.9 +78%
+78% +77%
Adjusted EBITDA(1)
Advanced Nutrition 11.5 11.5 -9% 6.2 7.2 -21%
0% -14%
Genetics 6.0 5.7 +16% 3.4 2.4 +51%
5% +41%
- Net of fair value movements in biological assets 5.7 4.7 +32% 2.0 1.3 +67%
+22% +52%
Health 6.6 0.1 +6,957% 2.6 (0.5) +663%
+7,034% +669%
*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure
(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Trond Williksen, CEO, commented:
"Benchmark had an excellent first half, delivering double digit growth. We
continue to focus on achieving profitability and cash generation whilst making
good progress towards our medium-term objectives; we remain on track to
deliver strong growth for the year in line with market expectations.
"Our fundamentals are strong and we have significant opportunities to continue
building our track record of consistent growth. Aquaculture is a growth
industry, supported by robust megatrends. Benchmark is well positioned to play
an important role in helping the aquaculture industry deliver sustainable
growth and meet the needs of a rising population."
Presentation for analysts and institutional investors at 08.00 UK time (09.00
CET)
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 UK time.
The presentation will be held in person at Pareto Securities offices in Oslo
at Dronning Mauds gate 3, N‑0250 Oslo, Norway. If you would like to attend
in person, please contact Thea Naess at thea.naess@paretosec.com.
A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230523_3
(https://protect-eu.mimecast.com/s/QkqoCwjMxfNEly6c81Srh?domain=channel.royalcast.com)
(https://protect-eu.mimecast.com/s/QkqoCwjMxfNEly6c81Srh?domain=channel.royalcast.com)
A copy of the presentation can be found on the Company's website
https://www.benchmarkplc.com/investors/reports-presentations/
Equity Development webcast at 12.00 UK time
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers on
the day at 12.00 UK time. The webcast is open to all existing and potential
shareholders.
To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-
(https://protect-eu.mimecast.com/s/LBHoC0gvMUyqMlyCribDx?domain=equitydevelopment.co.uk)
2qresults-presentation-23may2023
(https://protect-eu.mimecast.com/s/LBHoC0gvMUyqMlyCribDx?domain=equitydevelopment.co.uk)
(https://protect-eu.mimecast.com/s/LBHoC0gvMUyqMlyCribDx?domain=equitydevelopment.co.uk)
A recording of the presentation will be available after the event on the
Equity Development website
(https://www.equitydevelopment.co.uk/research/tag/benchmark-holdings) .
(https://www.equitydevelopment.co.uk/research/tag/benchmark-holdings)
Enquiries
For further information, please contact:
Benchmark Holdings plc benchmark@mhpgroup.com (mailto:benchmark@mphgroup.com)
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
Freddie Barnfield, Duncan Monteith, Sher Shah
MHP Tel: 020 3128 899
Katie Hunt, Reg Hoare, Veronica benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
Farah
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth, animal health and welfare.
Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses the major aquaculture species in all the
major aquaculture regions around the world. Find out more at
www.benchmarkplc.com (http://www.benchmarkplc.com)
Management Report
Benchmark delivered an excellent performance in the first half of the year
continuing to build on its track record of consistent quarterly increase in
revenues and underlying profitability. Revenues were up 25% (19% at constant
currency) reaching £98.9m, and Adjusted EBITDA excluding fair value movements
from biological assets at £21.8m was up 47% (42% at constant currency)
against H1 FY22, translating into an Adjusted EBITDA margin excluding fair
value movements of 22% (H1 FY22: 19%). Adjusted EBITDA increased by 39% (36%
at constant currency) in the six-month period. The increase in Adjusted EBITDA
excluding fair value movements from biological assets derives primarily from
higher revenues, supported by ongoing cost control and operational leverage.
Higher revenues were reported across all business areas with Genetics revenues
increasing by 30%, Advanced Nutrition 8% and Health 78%. In Health and
Genetics, the impact from foreign currencies was not material, with revenue
growth at constant currency broadly in line with actual revenue growth.
Advanced Nutrition sales were aided by forex tailwinds, and revenue fell
slightly (-4%) in constant currency terms. Operating costs in H1 FY23 were
£24.0m, a 21% increase from the prior year. The increase reflects higher
activity levels and inflationary pressure. R&D expenses at £3.0m, were
7% below H1 FY22 and total R&D investment including capitalised
development costs was £3.2m, 30% below the prior year (H1 FY22: £4.6m).
Depreciation and amortisation were marginally above the prior year at £19.1m
(H1 FY22: £18.9m). Together with the increase in EBITDA, this led to an
improvement at Operating Profit level to £0.3m (H1 FY22: -£2.2m loss).
Adjusted Operating Profit excluding fair value movements from biological
assets increased by 193% to £11.4m. Taking into consideration conditions in
the end markets, performance was strong across all business areas.
Net finance costs for H1 FY23 were £2.2m (H1 FY22: £3.0m). The reduction
arises due to a credit of £2.7m arising in H1 relating to the ineffective
portion of the movement in the fair value of derivative financial instruments,
offset by higher forex losses in the period.
Loss before tax in H1 FY23 was £1.9m (H1 FY22: £5.1m). This included the
impact of significant exceptional costs in the period of £2.7m, largely
incurred in legal and professional costs in relation to the preparations for
listing the Group on the Oslo Børs. The figure contrasted with a £0.9m net
credit in H1 FY22 which included a credit of £1.2m for additional contingent
consideration received from disposals in previous years.
Total tax charge in H1 FY23 was £1.5m (H1 FY22: £3.6m) reflecting a change
in the mix in the territories in which the profits have been made, with losses
available to shelter profits in some territories. Loss after tax was £3.4m
(H1 FY22: £8.8m loss).
The Group reported a net operating cash inflow of £9.5m after an increase in
working capital of £4.2m (H1 FY22: £13.5m) and tax payments of £4.1m (H1
FY22: £3.0m). The increase in working capital is somewhat seasonal, but the
much lower increase year on year, in the context of increased activity,
results from our strong focus on managing our working capital closely towards
our goal of achieving positive cash generation.
Net cash outflow from investing activities was £11.5m (H1 FY22: £6.6m) of
which £8.0m related to the acquisition of the remaining minority stake in
Benchmark Genetics Iceland completed in February 2023. PPE capex was £3.3m
(H1 FY22: £5.1m).
Net cash inflow from financing activities of £6.8m (H1 FY22: £10.7m),
includes an equity raise of (net) £13.0m, net proceeds from debt refinancing
of £4.2m, and £4.7m of lease payments (H1 FY22: £4.8m). Interest charges in
the period were £4.0m (H1 FY22: £3.8m), as the higher cost of borrowing
offset the lower level of borrowings outstanding in the period. Our cash
position at the end of the period was £38.6m (H1 FY22: £46.3m), and net debt
including lease liabilities was £66.3m (H1 FY22: £81.4m).
Advanced Nutrition
Advanced Nutrition delivered a strong result despite soft shrimp markets in
the first half of the year demonstrating the success of a renewed commercial
focus and agile operation. Revenues for the first half were up 8% at £45.3m
while Adjusted EBITDA was flat against the same period in the previous year at
£11.5m.
Softness in the shrimp markets resulted from subdued demand from key import
markets, inventory levels across the supply chain and higher input costs,
primarily in South East Asia, while Ecuador was more robust. We expect an
uplift in shrimp production as consumer confidence picks up and inventory
levels normalise. Conditions in the marine fish sector were positive partially
offsetting softness in the shrimp market.
In transactional currency, by product area, Artemia sales were up 3% and
Health sales were up by 22% while Diets saw a 14% decrease. On the same
basis by region, Asia Pacific and South East Asia were most affected by
conditions in the shrimp market leading to a reduction in sales of 13% and 19%
respectively. Conversely, the Americas reported growth of 8% while sales in
Europe increased 6%.
With a leading position in the market, deep customer relations, operational
agility and commercial focus our Advanced Nutrition business is well placed to
mitigate the temporary weakness and take every opportunity to strengthen our
position in the market.
Genetics
Genetics delivered strong performance in the first half of the year with
revenues of £34.5m, 30% above the prior year (H1 FY22: £26.6m) driven by
higher salmon egg sales and harvest revenues. Adjusted EBITDA for H1 FY23
excluding fair value movements of biological assets was £5.7m, 22% ahead of
the prior year (H1 FY22: £4.7m). Including fair value movements Adjusted
EBITDA for the first half was £6.0m, 5% ahead of the same period last year.
Revenues from salmon eggs increased by 45% driven by Norway and Iceland, while
harvest revenues grew by 9%. We made commercial progress in Chile with new
customer wins. In addition, we obtained "disease free compartment status"
from the Chilean regulator, Senapesca. This is an important biosecurity
endorsement which will enable the Company to export salmon eggs from Chile
thereby opening new avenues to utilise our installed capacity.
In Q2 we completed the configuration of the Salten facility, to reach 150m
salmon egg capacity (currently 140m eggs) which will be in place from FY24
onwards. This marks the end of an investment journey where the Company has
increased its total salmon egg capacity to 400m eggs, comprising 150m in
Salten, Norway, 200m in Iceland and 50m in Chile.
In shrimp we continued our efforts to enhance and tailor genetic traits to
local markets and trials in local markets are underway. We have decreased
the intensity of our commercial efforts while the trials are ongoing. Shrimp
sales were £0.7m in the period (H1 FY22: £0.8m).
Innovation is a core component of our Genetics strategy and we continue to
strengthen our capability in the team. We have also enhanced our capacity for
genotyping, reducing the costs for our own programmes and enabling us to offer
genotyping as part of our offering in genetics services.
During the period the Company acquired the remaining 10.52% minority interest
in its subsidiary Benchmark Genetics Iceland ensuring Benchmark receives the
full benefit from its successful salmon genetics business in Iceland.
Benchmark Genetics Iceland represents c.50% of the Group's 400m salmon egg
capacity.
Health
Revenues in H1 FY23 increased to £19.1m (H1 FY22: £10.7m) with higher
sales from both Ectosan® Vet and CleanTreat® and Salmosan® Vet. Ectosan®
Vet and CleanTreat® sales were £12.9m (H1 FY22: £8.6m) of which £4.5m (H1
FY22: £2.2m) related to recharging of vessel and fuel costs. There is growing
adoption of our highly efficacious sea lice solution and we continue to work
with our partners MMC and Salt Ship Design to develop a streamlined
infrastructure for CleanTreat® which will further facilitate adoption in the
market.
Salmosan® Vet sales were £6.2m, 192% ahead of the prior year supported by
the success of a new marketing label.
Adjusted EBITDA for the business area was £6.6m (H1 FY22: £0.1m).
Q2 FY23 commentary
The Group reported revenue of £44.4m, 13% above prior year of £39.2m. This
was driven by revenue growth in Health and Genetics which reported revenue
+77% and +14% higher than Q2 FY22 respectively. Revenues in Advanced Nutrition
were marginally down -1% driven by low current demand in the shrimp markets as
mentioned above.
Adjusted EBITDA excluding fair value uplift from biological assets was £9.7m,
32% ahead of the prior year and 28% higher on a constant currency basis (Q2
FY22: £7.3m), reflecting higher revenues, operational leverage and good cost
control. By business area, Health was up more than sixfold, Genetics was up
52% while Advanced Nutrition reported a decrease in Adjusted EBITDA of 14%,
despite forex tailwinds mitigating the reduction.
Operating costs of £12.3m were 23% above last year (Q2 FY22: £10.0m) driven
by increased activity and inflationary pressure. R&D expenses of £1.4m
were 10% below the prior year (Q2 FY22: £1.6m) and represented 3% of Group
revenues (Q2 FY22: 4%). Depreciation and amortisation was £9.0m (Q2 FY22:
£10.0m), leading to a Group operating profit of £0.4m (Q2 FY22: £0.7m
loss).
Net finance costs of £2.4m for the quarter were £1.6m higher than the same
period last year (Q2 FY22: £0.8m), mainly due to forex losses of £0.7m (Q3
FY22: gain of £0.6m) in the period.
The tax charge of £0.7m (Q2 FY22: £2.2m) reflects a change in the mix of
territories in which taxable profits were made, leading loss after tax for the
quarter at £2.7m (Q2 FY22: loss of £3.7m).
Update on Oslo Børs listing
As previously announced, the Company conducted a consultation with
shareholders regarding a potential delisting from AIM and uplisting to the
Oslo Børs. Based on the feedback received the Board has decided to maintain
its current listings on Euronext Growth Oslo and on AIM for the foreseeable
future.
The Board continues to believe that in the medium term the company could
benefit from uplisting to the Oslo Børs as the leading venue for seafood and
aquaculture companies. An uplisting will be reviewed as part of the Group's
ongoing strategy to enhance the Group's positioning and shareholder value.
Outlook and current trading
The Group had an excellent first half, delivering 25% growth in revenues and
trading in line with market expectations. We continued to focus on achieving
profitability and cash generation whilst making good progress towards our
medium-term objectives.
The Group communicated its medium term (3-5 year) financial objectives in May
2022 and since then has reported significant progress as shown in the table
below:
Medium term objective FY21 FY22 H123
Revenue Growth per annum 15-18% 18% 27% 25%
Adj. EBITDA Margin 25-30% 16% 20% 22%
(period end)
Cashflow conversion ratio(1) 70-80% 30% 35% 43%
Free cashflow as % of sales(2) 10-15% (17%) (8%) 1%
1. Cash generated from operations after working capital and
taxes as percentage of Adj. EBITDA
2. Free cash flow: Net cash from operating activities less capex
and lease payments (excluding cash interest)
Looking forward to the second half of the year there is good visibility of
salmon egg sales in Genetics and we will continue to progress our growth
vectors of salmon in Chile and shrimp genetics, which will be key areas of
focus in the coming periods. In Advanced Nutrition we expect conditions in
the shrimp market to remain unchanged in the short term and while this poses a
challenge to growth, we are confident that we have a leading and dynamic
organisation capable of mitigating the impact from market conditions whilst
taking advantage to increase our market share where possible. In Health, we
expect Q3 sales to reflect the seasonally low sea lice treatment season,
thereafter increasing in Q4.
Our fundamentals are strong and we have significant opportunities to continue
building our track record of consistent growth. Since completing the Group's
restructuring in 2020 we have delivered a 62% increase in revenue and 117%
increase in Adj. EBITDA, whilst steadily reducing net debt. Aquaculture is a
growth industry, supported by robust megatrends. As a leading aquaculture
biotechnology company, Benchmark is well positioned to play an important role
in helping the aquaculture industry deliver sustainable growth and meet the
needs of a rising population.
Benchmark Holdings plc
Consolidated Income Statement for the period ended 31 March 2023
All figures in £000's Notes Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Revenue 4 44,367 39,233 98,862 79,247 158,277
Cost of sales (19,549) (19,210) (49,817) (39,725) (75,149)
Gross profit 24,818 20,023 49,045 39,522 83,128
Research and development costs (1,435) (1,590) (2,998) (3,237) (6,691)
Other operating costs (12,290) (9,984) (24,043) (19,907) (44,661)
Share of (loss)/profit of equity-accounted investees, net of tax - (24) 56 (528) (595)
Adjusted EBITDA² 11,093 8,425 22,060 15,850 31,181
Exceptional - restructuring, disposal and acquisition related items 5 (1,716) 908 (2,688) 908 16
EBITDA¹ 9,377 9,333 19,372 16,758 31,197
Depreciation and impairment (4,551) (5,557) (9,166) (10,052) (19,897)
Amortisation and impairment (4,410) (4,484) (9,912) (8,872) (19,161)
Operating profit/(loss) 416 (708) 294 (2,166) (7,861)
Finance cost (3,223) (2,684) (10,353) (4,747) (20,057)
Finance income 791 1,930 8,143 1,769 4,741
Loss before taxation (2,016) (1,462) (1,916) (5,144) (23,177)
Tax on loss 6 (704) (2,189) (1,483) (3,616) (7,274)
Loss for the period (2,720) (3,651) (3,399) (8,760) (30,451)
Loss for the period attributable to:
- Owners of the parent (2,858) (3,775) (4,141) (9,132) (32,087)
- Non-controlling interest 138 124 742 372 1,636
(2,720) (3,651) (3,399) (8,760) (30,451)
Earnings per share
Basic loss per share (pence) 7 (0.40) (0.54) (0.57) (1.32) (4.60)
Diluted loss per share (pence) 7 (0.40) (0.54) (0.57) (1.32) (4.60)
1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment
2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items
Benchmark Holdings plc
Consolidated Statement of Comprehensive Income for the period ended 31 March
2023
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Loss for the period (2,720) (3,651) (3,399) (8,760) (30,451)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences (5,973) 9,812 (24,013) 7,201 47,606
Cash flow hedges - changes in fair value 217 3,082 (299) 2,948 2,627
Cash flow hedges - reclassified to profit or loss (179) 63 (292) 178 2,546
Total comprehensive income for the period (8,655) 9,306 (28,003) 1,567 22,328
Total comprehensive income for the period attributable to:
- Owners of the parent (8,295) 8,784 (28,046) 836 20,326
- Non-controlling interest (360) 522 43 731 2,002
(8,655) 9,306 (28,003) 1,567 22,328
The accompanying notes are an integral part of this consolidated financial
information.
Benchmark Holdings plc
Consolidated Balance Sheet as at 31 March 2023
31 March 2023 31 March 2022 30 September 2022
All figures in £000's Notes (unaudited) (unaudited) (audited)
Assets
Property, plant and equipment 76,414 81,568 81,900
Right-of-use assets 22,365 31,360 27,034
Intangible assets 215,077 226,912 245,264
Equity-accounted investees 3,136 2,821 3,113
Other investments 14 15 15
Biological and agricultural assets 20,605 17,089 20,878
Non-current assets 337,611 359,765 378,204
Inventories 27,129 22,140 29,813
Biological and agricultural assets 22,550 24,294 25,780
Trade and other receivables 48,433 47,275 56,377
Cash and cash equivalents 38,647 46,294 36,399
Current assets 136,759 140,003 148,369
Total assets 474,370 499,768 526,573
Liabilities
Trade and other payables (29,723) (33,284) (44,324)
Loans and borrowings 8 (22,115) (13,546) (17,091)
Corporation tax liability (8,413) (7,733) (10,211)
Provisions (1,574) (551) (1,631)
Current liabilities (61,825) (55,114) (73,257)
Loans and borrowings 8 (82,878) (114,185) (93,045)
Other payables (6,257) (936) (8,996)
Deferred tax (24,293) (27,524) (27,990)
Non-current liabilities (113,428) (142,645) (130,031)
Total liabilities (175,253) (197,759) (203,288)
Net assets 299,117 302,009 323,285
Issued capital and reserves attributable to owners of the parent
Share capital 9 739 704 704
Additional paid-in share capital 9 37,924 420,824 420,824
Capital redemption reserve 5 5 5
Retained earnings 201,962 (162,696) (185,136)
Hedging reserve (1,294) (2,750) (703)
Foreign exchange reserve 54,391 37,307 77,705
Equity attributable to owners of the parent 293,727 293,394 313,399
Non-controlling interest 5,390 8,615 9,886
Total equity and reserves 299,117 302,009 323,285
The accompanying notes are an integral part of this consolidated financial
information.
Benchmark Holdings plc
Consolidated Statement of Changes in Equity for the period ended 31 March 2023
Share Additional paid-in share capital* Other Hedging Retained Total attributable Non- Total
capital
reserves
reserve
earnings
to equity holders of
controlling
equity
parent
interest
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (4,141) (4,141) 742 (3,399)
Other comprehensive income/(loss) - - (23,314) (591) - (23,905) (699) (24,604)
Total comprehensive income/(loss) for the period - - (23,314) (591) (4,141) (28,046) 43 (28,003)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (1,650) - - - (1,650) - (1,650)
Cancellation of part of share premium account (note 9) - (394,235) - - 394,235 - - -
Share-based payment - - - - 475 475 - 475
Total contributions by and distributions to owners 35 (382,900) - - 394,710 11,845 - 11,845
Changes in ownership
Acquisition of NCI - - - - (3,470) (3,470) (4,539) (8,009)
Total changes in ownership interests - - - - (3,470) (3,470) (4,539) (8,009)
Total transactions with owners of the Company 35 (382,900) - - 391,240 8,375 (4,539) 3,836
As at 31 March 2023 (unaudited) 739 37,924 54,396 (1,294) 201,963 293,728 5,390 299,118
As at 1 October 2021 (audited) 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income/(loss)for the period
Profit/(loss) for the period - - - - (9,132) (9,132) 372 (8,760)
Other comprehensive income/(loss) - - 6,842 3,126 - 9,968 359 10,327
Total comprehensive income/(loss) for the period - - 6,842 3,126 (9,132) 836 731 1,567
Contributions by and distributions to owners
Share issue 34 20,704 - - - 20,738 - 20,738
Share issue costs recognised through equity - (562) - - - (562) - (562)
Share-based payment - - - - 667 667 - 667
Total contributions by and distributions to owners 34 20,142 - - 667 20,843 - 20,843
Changes in ownership
Total changes in ownership interests - - - - - - - -
Total transactions with owners of the Company 34 20,142 - - 667 20,843 - 20,843
As at 31 March 2022 (unaudited) 704 420,824 37,312 (2,750) (162,696) 293,394 8,615 302,009
As at 1 October 2021 (audited) 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (32,087) (32,087) 1,636 (30,451)
Other comprehensive income/(loss) - - 47,240 5,173 - 52,413 366 52,779
Total comprehensive income/(loss) for the period - - 47,240 5,173 (32,087) 20,326 2,002 22,328
Contributions by and distributions to owners
Share issue 34 20,704 - - - 20,738 - 20,738
Share issue costs recognised through equity - (562) - - - (562) - (562)
Share-based payment - - - - 1,182 1,182 - 1,182
Total contributions by and distributions to owners 34 20,142 - - 1,182 21,358 - 21,358
Changes in ownership
Total changes in ownership interests - - - - - - - -
Total transactions with owners of the Company 34 20,142 - - 1,182 21,358 - 21,358
As at 30 September 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve
Benchmark Holdings plc
Consolidated Statement of Cashflows for the period ended 31 March 2023
31 March 2023 31 March 2022 30 September 2022
Notes (unaudited) (unaudited) (audited)
Cash flows from operating activities
Loss for the period (3,399) (8,760) (30,451)
Adjustments for:
Depreciation and impairment of property, plant and equipment 4,248 4,187 8,602
Depreciation and impairment of right-of-use assets 4,918 5,865 11,295
Amortisation and impairment of intangible fixed assets 9,912 8,872 19,161
Loss on sale of property, plant and equipment (36) - (43)
Finance income (320) (225) (319)
Finance costs 1,715 3,714 18,437
Increase in fair value of contingent consideration receivable - (909) (1,203)
Share of profit/(loss) of equity-accounted investees, net of tax (55) 528 595
Foreign exchange losses (1,104) 841 (3,985)
Share-based payment expense 475 667 1,182
Other adjustments for non-cash items - - (276)
Tax charge 1,482 3,616 7,274
Decrease/(increase) in trade and other receivables 6,071 108 (8,511)
Decrease/(increase) in inventories 2,517 (1,610) (5,406)
Decrease/(increase) in biological and agricultural assets 893 (1,635) (6,099)
(Decrease)/increase in trade and other payables (13,673) (10,317) 6,946
(Decrease)/increase in provisions (13) (12) 1,058
13,631 4,930 18,257
Income taxes paid (4,141) (2,975) (7,447)
Net cash flows generated from operating activities 9,490 1,955 10,810
Investing activities
Acquisition of minority interests in subsidiaries, net of cash acquired 12 (8,009) - -
Purchase of investments (307) (48) (378)
Receipts from disposal of investments - - 1,544
Purchases of property, plant and equipment (3,254) (5,084) (10,808)
Purchase of intangibles (77) (1,523) (205)
Capitalised research and development costs (197) - (1,708)
Proceeds from sale of fixed assets 77 3 220
Interest received 319 25 119
Net cash flows used in investing activities (11,448) (6,627) (11,216)
Financing activities
Proceeds of share issues 13,020 20,782 20,737
Share-issue costs recognised through equity (1,650) (607) (562)
Proceeds from bank or other borrowings 21,393 - 67,939
Repayment of bank or other borrowings (16,560) (939) (74,874)
Capitalised borrowing costs (591) - -
Interest and finance charges paid (4,082) (3,757) (9,629)
Repayments of lease liabilities (4,689) (4,769) (10,533)
Net cash inflow/(outflow) from financing activities 6,841 10,710 (6,922)
Net increase/(decrease) in cash and cash equivalents 4,883 6,038 (7,328)
Cash and cash equivalents at beginning of period 36,399 39,460 39,460
Effect of movements in exchange rate (2,634) 796 4,267
Cash and cash equivalents at end of period 38,648 46,294 36,399
Benchmark Holdings plc
Unaudited notes to the quarterly financial statements for the period ended 31
March 2023
1. Basis of preparation
Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the six months ended 31 March 2023 comprises those of the Company and
its subsidiaries (together referred to as the 'Group').
These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2022 were prepared in accordance with UK adopted
international accounting standards in conformity with the requirements of the
Companies Act 2006 as it applies to companies reporting under those standards
("Adopted IFRS") and are available from the Company's website at
www.benchmarkplc.com (http://www.benchmarkplc.com) .
The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2022 and the unaudited financial information in
the Quarterly Financial Report for the six months ended 31 March 2022. The
comparative figures for the financial year ended 30 September 2022 are not the
Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 30 November 2022 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not include a reference to any matters to which the
external auditor drew attention by way of emphasis without qualifying their
report, and (iii) did not contain a statement under section 498(2) or (3) of
the Companies Act 2006.
Statement of Compliance
These consolidated quarterly financial statements have been prepared in
accordance with UK and EU adopted IAS 34 'Interim Financial Reporting'. These
financial statements do not include all of the information required for the
full annual financial statements and should be read in conjunction with the
Group's last annual consolidated financial statements as at and for the year
ended 30 September 2022. These consolidated quarterly financial statements
were approved by the Board of Directors on 23 May 2023.
Going concern
The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.
As at 31 March 2023 the Group had net assets of £299.1m (30 September 2022:
£323.3m), including cash of £38.6m (30 September 2022: £36.4m) as set out
in the consolidated balance sheet. The Group made a loss for the six months of
£3.4m (year ended 30 September 2022: loss £30.5m).
As noted in the Management Report, the business has continued to perform well
on the back of a good year in FY22. All of the business areas have performed
in line with or ahead of management expectations. The Directors have reviewed
forecasts and cash flow projections for a period of at least 12 months
including downside sensitivity assumptions in relation to trading performance
across the Group to assess the impact on the Group's trading and cash flow
forecasts and on the forecast compliance with the covenants included within
the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and demand for artemia feeds in certain territories. Mitigating
measures within the control of management have been identified should they be
required in response to these sensitivities, including reductions in areas of
discretionary spend, tight control over new hires, and deferral of capital
projects.
The refinancing exercise which commenced in FY22 was completed in Q1 FY23, so
that adequate finance facilities are in place, and with financial instruments
in place to fix interest rates and opportunities available to mitigate
globally high inflation rates, the Group continues to show resilience against
the global economic pressures, caused mainly by the conflict in Eastern
Europe. The Directors are therefore confident that even under all of the above
sensitivity analysis, the Group has sufficient liquidity and resources
throughout the period under review whilst still maintaining adequate headroom
against the borrowing covenants and remain confident that the Group has
adequate resources to continue to meet its liabilities as and when they fall
due within the period of 12 months from the date of approval of these
financial statements. Based on their assessment, the Directors believe it
remains appropriate to prepare the financial statements on a going concern
basis.
2. Accounting policies
The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2022.
Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.
Alternative performance measures ('APMs')
The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by EU or UK-adopted
IFRS. These APMs may not be directly comparable with other companies' APMs,
and the Directors do not intend these as a substitute for, or superior to,
IFRS measures.
Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 10).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.
Use of estimates and judgements
The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.
In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2022.
3. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
· Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.
· Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
· Health - the segment provides health products and services to the
global aquaculture market.
3. Segment information (continued)
In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy
was applied consistently throughout the current and prior period.
Segmental Revenue
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Genetics 13,042 11,408 34,481 26,603 58,008
Advanced Nutrition 22,644 22,974 45,324 42,033 80,286
Health 8,692 4,916 19,077 10,693 20,135
Corporate 1,436 1,406 2,873 2,812 5,120
Inter-segment sales (1,447) (1,471) (2,893) (2,894) (5,272)
Total 44,367 39,233 98,862 79,247 158,277
Segmental Adjusted EBITDA
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Genetics 3,420 2,428 5,983 5,691 15,980
Advanced Nutrition 6,169 7,154 11,466 11,474 19,017
Health 2,583 (454) 6,650 93 108
Corporate (1,079) (703) (2,039) (1,408) (3,924)
Total 11,093 8,425 22,060 15,850 31,181
Reconciliations of segmental information to IFRS measures
Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
taxation
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Total reportable segment Adjusted EBITDA 12,172 9,128 24,099 17,258 35,105
Corporate Adjusted EBITDA (1,079) (703) (2,039) (1,408) (3,924)
Adjusted EBITDA 11,093 8,425 22,060 15,850 31,181
Exceptional - restructuring, disposal and acquisition related items (1,716) 908 (2,688) 908 16
Depreciation and impairment (4,551) (5,557) (9,166) (10,052) (19,897)
Amortisation and impairment (4,410) (4,484) (9,912) (8,872) (19,161)
Net finance costs (2,432) (754) (2,210) (2,978) (15,316)
Loss before taxation (2,016) (1,462) (1,916) (5,144) (23,177)
4. Revenue
The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2022. The Group's revenue is derived from
contracts with customers.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).
Sale of goods and provision of services
3 months ended 31 March 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 11,083 22,635 6,115 - - 39,833
Provision of services 1,957 - 2,577 - - 4,534
Inter-segment sales 2 9 - 1,436 (1,447) -
13,042 22,644 8,692 1,436 (1,447) 44,367
3 months ended 31 March 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 9,872 22,945 2,594 - - 35,411
Provision of services 1,500 - 2,322 - - 3,822
Inter-segment sales 36 29 - 1,406 (1,471) -
11,408 22,974 4,916 1,406 (1,471) 39,233
6 months ended 31 March 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 32,204 45,307 13,564 - - 91,075
Provision of services 2,274 - 5,513 - - 7,787
Inter-segment sales 3 17 - 2,873 (2,893) -
34,481 45,324 19,077 2,873 (2,893) 98,862
6 months ended 31 March 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 24,381 41,993 5,845 - - 72,219
Provision of services 2,180 - 4,848 - - 7,028
Inter-segment sales 42 40 - 2,812 (2,894) -
26,603 42,033 10,693 2,812 (2,894) 79,247
4. Revenue (continued)
Sale of goods and provision of services (continued)
12 months ended 30 September 2022 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 53,978 80,191 13,528 - - 147,697
Provision of services 3,973 - 6,607 - - 10,580
Inter-segment sales 57 95 - 5,120 (5,272) -
58,008 80,286 20,135 5,120 (5,272) 158,277
Primary geographical markets
3 months ended 31 March 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 6,177 252 6,157 - - 12,586
India - 2,822 - - - 2,822
Turkey - 2,528 - - - 2,528
Greece - 2,002 - - - 2,002
Faroe Islands 2,224 - 119 - - 2,343
Ecuador 9 1,832 - - - 1,841
United Kingdom 814 8 - - - 822
Chile 1,121 9 88 - - 1,218
Vietnam - 2,330 - - - 2,330
Rest of Europe 1,680 1,716 - - - 3,396
Rest of World 1,015 9,136 2,328 - - 12,479
Inter-segment sales 2 9 - 1,436 (1,447) -
13,042 22,644 8,692 1,436 (1,447) 44,367
3 months ended 31 March 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 6,115 211 4,288 - - 10,614
India 260 3,711 - - - 3,971
Turkey - 2,238 - - - 2,238
Greece - 1,832 - - - 1,832
Faroe Islands 1,709 5 147 - - 1,861
Ecuador - 1,227 - - - 1,227
United Kingdom 899 14 30 - - 943
Chile 224 5 150 - - 379
Vietnam - 3,014 - - - 3,014
Rest of Europe 1,590 1,278 - - - 2,868
Rest of World 575 9,410 301 - - 10,286
Inter-segment sales 36 29 - 1,406 (1,471) -
11,408 22,974 4,916 1,406 (1,471) 39,233
4. Revenue (continued)
Primary geographical markets (continued)
6 months ended 31 March 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 23,061 342 14,452 - - 37,855
India - 7,025 - - - 7,025
Turkey 2 4,732 - - - 4,734
Greece - 4,271 - - - 4,271
Faroe Islands 3,319 - 348 - - 3,667
Ecuador 29 3,572 - - - 3,601
United Kingdom 1,551 27 42 - - 1,620
Chile 1,133 11 342 - - 1,486
Vietnam - 5,025 - - - 5,025
Rest of Europe 3,742 3,338 - - - 7,080
Rest of World 1,641 16,964 3,893 - - 22,498
Inter-segment sales 3 17 - 2,873 (2,893) -
34,481 45,324 19,077 2,873 (2,893) 98,862
6 months ended 31 March 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 15,794 323 8,956 - - 25,073
India 400 7,719 - - - 8,119
Turkey - 3,932 - - - 3,932
Greece - 3,471 - - - 3,471
Faroe Islands 2,856 28 118 - - 3,002
Ecuador - 2,291 - - - 2,291
United Kingdom 2,601 6 277 - - 2,884
Chile 340 5 553 - - 898
Vietnam - 6,009 - - - 6,009
Rest of Europe 3,361 2,581 - - - 5,942
Rest of World 1,209 15,628 789 - - 17,626
Inter-segment sales 42 40 - 2,812 (2,894) -
26,603 42,033 10,693 2,812 (2,894) 79,247
4. Revenue (continued)
Primary geographical markets (continued)
12 months ended 30 September 2022 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 34,666 965 15,571 - - 51,202
India 619 12,001 - - - 12,620
Turkey - 6,419 - - - 6,419
Greece 2 6,197 - - - 6,199
Faroe Islands 5,465 9 587 - - 6,061
Ecuador 18 6,472 - - - 6,490
United Kingdom 4,318 93 199 - - 4,610
Chile 1,006 15 871 - - 1,892
Vietnam - 10,512 - - - 10,512
Rest of Europe 7,110 4,056 - - - 11,166
Rest of World 4,747 33,452 2,907 - - 41,106
Inter-segment sales 57 95 (0) 5,120 (5,272) (0)
58,008 80,286 20,135 5,120 (5,272) 158,277
5. Exceptional - restructuring, disposal, and acquisition related
items
Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Exceptional restructuring costs 1,716 - 2,688 - 1,229
Income in relation to disposals - (908) - (908) (1,245)
Total exceptional items 1,716 (908) 2,688 (908) (16)
Exceptional restructuring costs for the quarter include £1,666,000 (YTD 2023:
£2,553,000; FY 2022: £843,000) of legal and professional costs in relation
to preparing for listing the Group on the Oslo stock exchange, and £50,000
(YTD 2023: £135,000; FY 2022: £276,000) relating to other restructuring
costs.
Income in relation to disposals for Q2 2022 and YTD Q2 2022 of £908,000
relate to an increase in the fair value of contingent consideration receivable
following the disposal of Improve International Limited in 2020. Further to
this, the balance in FY 2022 includes £294,000 of additional contingent
consideration received relating to the disposal of Aquaculture UK in 2020.
6. Taxation
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Analysis of charge in period
Current tax:
Current income tax expense on profits for the period 997 2,642 2,835 5,007 11,727
Adjustment in respect of prior periods - - - - (39)
Total current tax charge 997 2,642 2,835 5,007 11,688
Deferred tax:
Origination and reversal of temporary differences (293) (453) (1,352) (1,391) (4,414)
Deferred tax movements in respect of prior periods - - - - -
Total deferred tax credit (293) (453) (1,352) (1,391) (4,414)
- -
Total tax charge 704 2,189 1,483 3,616 7,274
7. Loss per share
Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.
Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Loss attributable to equity holders of the parent (£000) (2,858) (3,775) (4,141) (9,132) (32,087)
Weighted average number of shares in issue (thousands) 723,173 703,926 724,505 692,474 698,233
Basic loss per share (pence) (0.40) (0.54) (0.57) (1.32) (4.60)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.
Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.
A total of 4,312,880 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2022: 6,240,304 and 31 March 2022: 5,184,054). These potential ordinary shares
could dilute earnings/loss per share in the future.
8. Loans and borrowings
YTD Q2 2023 YTD Q2 2022 FY 2022
All figures in £000's (unaudited) (unaudited) (audited)
Non-Current
2025 750m NOK Loan notes 56,756 - 61,054
2023 850m NOK Loan notes - 76,353 -
Bank borrowings 16,974 18,917 17,226
Lease liabilities 9,148 18,915 14,765
82,878 114,185 93,045
Current
Bank borrowings 9,421 1,648 5,569
Lease liabilities 12,694 11,899 11,522
22,115 13,546 17,091
Total loans and borrowings 104,993 127,732 110,136
On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments. The proceeds were used to repay its existing NOK 850m floating rate
listed bond, originally raised in June 2019. The bond was listed on the Oslo
Stock Exchange during the current period on 12 April 2023.
On 21 November 2022, the Group refinanced its USD15m RCF, which was provided
by DNB Bank ASA (50%) and HSBC UK Bank PLC (50%), with a secured GBP20m RCF
provided by DNB Bank ASA, maturing on 27 June 2025. The margin on this
facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the
leverage of the Group above the relevant risk-free reference or IBOR rates
depending on which currency is drawn.
On 15 February 2023, the Group drew down €9,000,000 on the GBP20,000 RCF
leaving £12,110,000 undrawn as at 31 March 2023.
Additionally, during the period, on 1 November 2022, the Group's Nordea Bank
term loan of NOK 165.6m, which had a term loan of five years ending in
November 2023 and interest rate of 2.5% above three month NIBOR, was
refinanced together with an existing undrawn overdraft facility into a new
loan facility of NOK 179.5m with a new maturity date in a further five years
no later than 15 January 2028. Other terms of this facility remain the same.
9. Share capital and additional paid-in share capital
Number Share Capital Additional paid-in
share capital
Allotted, called up and fully paid £000 £000
Ordinary shares of 0.1 pence each
Balance at 30 September 2022 703,960,798 704 420,824
Shares issued through placing and open offer 35,189,350 35 11,335
Cancellation of part of the share premium account - - (394,235)
Exercise of share options 127,321 - -
Balance at 31 March 2023 739,277,469 739 37,924
On 15 December 2022, the Company issued 35,189,350 new ordinary shares of 0.1
pence each by way of a placing and subscriptions at an issue price of 37.0
pence per share. Gross proceeds of £13.0m were received for the placing and
subscription shares. Non-recurring costs of £1.7m were in relation to the
share issues and this has been charged to the share premium account (presented
within additional paid-in share capital).
The share premium account is used to record the aggregate amount of value of
the premiums paid when the Company's shares are issued/redeemed at a premium.
On 20 March 2023, part of the Company's share premium account was cancelled
following the confirmation of the capital reduction by the High Court of
England and Wales on 14 March 2023 and the subsequent registration of the
court order with the Registrar of Companies. The capital reduction created
additional distributable reserves to the value of £394,235,072.
10. Alternative performance measures and other metrics
Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.
Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.
Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.
Adjusted Operating Profit is operating profit/loss before exceptional items
and amortisation and impairment of intangible assets excluding development
costs as reconciled below.
Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.
10. Alternative performance measures and other metrics (continued)
Reconciliation of Adjusted Operating Profit to Operating Loss
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Revenue 44,367 39,233 98,862 79,247 158,277
Cost of sales (19,549) (19,210) (49,817) (39,725) (75,149)
Gross profit 24,818 20,023 49,045 39,522 83,128
Research and development costs (1,435) (1,590) (2,998) (3,237) (6,691)
Other operating costs (12,290) (9,984) (24,043) (19,907) (44,661)
Depreciation and impairment (4,551) (5,557) (9,166) (10,052) (19,897)
Amortisation of capitalised development costs (610) (448) (1,227) (896) (2,165)
Share of loss of equity accounted investees net of tax - (24) 56 (528) (595)
Adjusted operating profit 5,932 2,420 11,667 4,902 9,119
Exceptional - restructuring, disposal and acquisition related items (1,716) 908 (2,688) 908 16
Amortisation and impairment of intangible assets excluding development costs (3,800) (4,036) (8,685) (7,976) (16,996)
Operating profit/(loss) 416 (708) 294 (2,166) (7,861)
Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Loss before taxation (2,016) (1,462) (1,916) (5,144) (23,177)
Exceptional - restructuring, disposal and acquisition related items 1,716 (908) 2,688 (908) (16)
Amortisation and impairment of intangible assets excluding development costs 3,800 4,036 8,685 7,976 16,996
Adjusted profit before tax 3,500 1,666 9,457 1,924 (6,197)
Other Metrics
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Total R&D Investment
Research and development costs 1,435 1,590 2,998 3,237 6,691
Internal capitalised development costs 144 777 198 1,404 1,708
Total R&D investment 1,579 2,367 3,196 4,641 8,399
All figures in £000's Q2 2023 Q2 2022 YTD Q2 2023 YTD Q2 2022 FY 2022
(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
Adjusted EBITDA excluding fair value movement in biological assets
Adjusted EBITDA 11,093 8,425 22,060 15,850 31,181
Exclude fair value movement (1,401) (1,101) (247) (1,005) (1,595)
Adjusted EBITDA excluding fair value movement in biological assets 9,692 7,324 21,813 14,845 29,586
10. Alternative performance measures and other metrics (continued)
Liquidity
A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.
31 March 2023
All figures in £000's (unaudited)
Cash and cash equivalents 38,647
Undrawn bank facility 12,110
50,757
The undrawn bank facility relates to the RCF facility. At 31 March 2023,
£7.9m of the RCF was drawn (30 September 2022: £4.0m and 31 March 2022:
£nil), leaving £12.1m undrawn (30 September 2022: £9.4m and 31 March 2022:
£nil).
11. Net debt
Net debt is cash and cash equivalents less loans and borrowings.
31 March 2023 31 March 2022 30 September 2022
All figures in £000's (unaudited) (unaudited) (audited)
Cash and cash equivalents 38,647 46,294 36,399
Loans and borrowings (excluding lease liabilities) - current (9,421) (1,647) (5,569)
Loans and borrowings (excluding lease liabilities) - non-current (73,730) (95,270) (78,280)
Net debt excluding lease liabilities (44,504) (50,623) (47,450)
Lease liabilities - current (12,694) (11,899) (11,522)
Lease liabilities - non-current (9,148) (18,915) (14,765)
Net debt (66,346) (81,437) (73,737)
12. Purchase of minority interests in subsidiary companies
On 15 February 2023, the Group purchased the minority interest's shareholding
of 14,981,272 shares in Benchmark Genetics Iceland HF for €9,000,000.
Following this acquisition, Benchmark Genetics Limited, a subsidiary of
Benchmark Holdings PLC, now owns 100% of the share capital of Benchmark
Genetics Iceland HF.
On 6 February 2023, the Group exercised the put/call option in place to
purchase the final 20% of Benchmark Genetics USA Inc for 1 NOK. Following
this acquisition, Benchmark Genetics Limited, a subsidiary of Benchmark
Holdings PLC, now owns 100% of the share capital of Benchmark Genetics USA
Inc.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR SEIESEEDSEII